Phase II Clinical Trial of Neoadjuvant and Adjuvant Pembrolizumab in Resectable Local–Regionally Advanced Head and Neck Squamous Cell Carcinoma

医学 彭布罗利珠单抗 内科学 肿瘤科 头颈部鳞状细胞癌 危险系数 放射治疗 阶段(地层学) 头颈部癌 外科 癌症 置信区间 免疫疗法 生物 古生物学
作者
Trisha M. Wise‐Draper,Shuchi Gulati,Sarah Palackdharry,Benjamin H. Hinrichs,Francis P. Worden,Matthew Old,Neal E. Dunlap,John M. Kaczmar,Yash Patil,Muhammed Kashif Riaz,Alice Tang,Jonathan Mark,Chad Zender,Ann M. Gillenwater,Diana Bell,Nicky Kurtzweil,Maria Mathews,Casey L. Allen,Michelle Mierzwa,Keith Casper,Roman Jandarov,Mario Medvedovic,John Lee,Nusrat Harun,Vinita Takiar,Maura L. Gillison
出处
期刊:Clinical Cancer Research [American Association for Cancer Research]
卷期号:28 (7): 1345-1352 被引量:41
标识
DOI:10.1158/1078-0432.ccr-21-3351
摘要

Abstract Purpose: Patients with resected, local–regionally advanced, head and neck squamous cell carcinoma (HNSCC) have a one-year disease-free survival (DFS) rate of 65%–69% despite adjuvant (chemo)radiotherapy. Neoadjuvant PD-1 immune-checkpoint blockade (ICB) has demonstrated clinical activity, but biomarkers of response and effect on survival remain unclear. Patients and Methods: Eligible patients had resectable squamous cell carcinoma of the oral cavity, larynx, hypopharynx, or oropharynx (p16-negative) and clinical stage T3-T4 and/or two or more nodal metastases or clinical extracapsular nodal extension (ENE). Patients received neoadjuvant pembrolizumab 200 mg 1–3 weeks prior to surgery, were stratified by absence (intermediate-risk) or presence (high-risk) of positive margins and/or ENE, and received adjuvant radiotherapy (60–66 Gy) and concurrent pembrolizumab (every 3 weeks × 6 doses). Patients with high-risk HNSCC also received weekly, concurrent cisplatin (40 mg/m2). Primary outcome was one-year DFS. Secondary endpoints were one-year overall survival (OS) and pathologic response (PR). Safety was evaluated with CTCAE v5.0. Results: From February 2016 to October 2020, 92 patients enrolled. The median age was 59 years (range, 27–80), 30% were female, 86% had stage T3–T4, and 69% had ≥N2. At a median follow-up of 28 months, one-year DFS was 97% (95% CI, 71%–90%) in the intermediate-risk group and 66% (95% CI, 55%–84%) in the high-risk group. Patients with a PR had significantly improved one-year DFS relative to patients without response (93% vs. 72%, hazard ratio 0.29; 95% CI, 11%–77%). No new safety signals were identified. Conclusions: Neoadjuvant and adjuvant pembrolizumab increased one-year DFS rate in intermediate-risk, but not high-risk, HNSCC relative to historical control. PR to neoadjuvant ICB is a promising surrogate for DFS.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
落落完成签到,获得积分10
1秒前
Yan完成签到 ,获得积分10
2秒前
2秒前
谨慎的凝丝完成签到 ,获得积分10
3秒前
雨洋完成签到,获得积分10
4秒前
chi完成签到 ,获得积分10
5秒前
还单身的湘完成签到,获得积分10
7秒前
fyjlfy完成签到 ,获得积分10
7秒前
深情安青应助Nayvue采纳,获得10
8秒前
研友_Y59785完成签到,获得积分0
8秒前
Xiaoxiao发布了新的文献求助10
9秒前
初初见你完成签到,获得积分10
16秒前
19秒前
思源应助淡淡月饼采纳,获得20
19秒前
dd完成签到 ,获得积分10
20秒前
Nayvue发布了新的文献求助10
24秒前
未来的幻想完成签到,获得积分10
26秒前
Kvolu29完成签到,获得积分10
27秒前
长理物电强完成签到,获得积分10
28秒前
若安在完成签到,获得积分10
29秒前
完美世界应助潘特采纳,获得10
30秒前
拼搏问薇完成签到 ,获得积分10
30秒前
单薄乐珍完成签到 ,获得积分0
33秒前
张静枝完成签到 ,获得积分10
33秒前
六步郎完成签到,获得积分10
33秒前
啊怙纲完成签到 ,获得积分10
35秒前
量子星尘发布了新的文献求助10
37秒前
scott_zip完成签到 ,获得积分10
38秒前
gxl完成签到,获得积分0
42秒前
xxx完成签到 ,获得积分10
45秒前
45秒前
努力生活的小柴完成签到,获得积分10
47秒前
49秒前
tangyong完成签到,获得积分10
51秒前
长安发布了新的文献求助10
51秒前
SucceedIn完成签到,获得积分10
52秒前
53秒前
56秒前
海洋岩土12138完成签到 ,获得积分10
57秒前
lzz完成签到 ,获得积分10
57秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038184
求助须知:如何正确求助?哪些是违规求助? 3575908
关于积分的说明 11373872
捐赠科研通 3305715
什么是DOI,文献DOI怎么找? 1819255
邀请新用户注册赠送积分活动 892662
科研通“疑难数据库(出版商)”最低求助积分说明 815022